<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042600</url>
  </required_header>
  <id_info>
    <org_study_id>2599</org_study_id>
    <nct_id>NCT01042600</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation</brief_title>
  <official_title>Rescue Surfactant for Respiratory Distress Syndrome (RDS) in Newborns: Comparing Efficacy of Delivery Via Laryngeal Mask Airway to Delivery by Endotracheal Intubation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ONY</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LMA North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, newborn babies with respiratory distress syndrome (RDS), receiving oxygen via&#xD;
      nasal CPAP, and needing surfactant treatment will be randomized to standard delivery of&#xD;
      surfactant via and endotracheal tube airway(inserted after pre-medication for pain), or to&#xD;
      surfactant delivery via laryngeal mask airway (LMA). The intent is to remove the airways and&#xD;
      return babies to nasal CPAP, after surfactant is given. The primary outcome measure is the&#xD;
      rate of failure of initial surfactant therapy. Standardized failure criteria are reached: a)&#xD;
      early, if the baby is unable to be placed back on CPAP (needs mechanical ventilation) or, b)&#xD;
      late, if the baby requires retreatment with surfactant within 8 hours or more than 2 doses of&#xD;
      surfactant.&#xD;
&#xD;
      The objective of this protocol is to reduce the need for endotracheal intubation and&#xD;
      mechanical ventilation in preterm neonates with RDS needing rescue surfactant therapy by&#xD;
      instilling surfactant though an LMA, while achieving comparable efficacy of surfactant&#xD;
      treatment.&#xD;
&#xD;
      The hypothesis is that surfactant treatment through an LMA will decrease the proportion of&#xD;
      babies with RDS who require mechanical ventilation or subsequent intubation, when compared&#xD;
      with standard surfactant treatment following sedation and endotracheal intubation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Respiratory Distress Syndrome (RDS) due to deficiency of lung surfactant is common in preterm&#xD;
      newborns. Early treatment with surfactant improves oxygenation, reduces the need for&#xD;
      subsequent mechanical ventilation, decreases the incidence of pulmonary air leaks and chronic&#xD;
      lung disease and it also reduces mortality in extremely premature newborns. Optimal treatment&#xD;
      of RDS includes surfactant therapy and avoidance of invasive mechanical ventilation by using&#xD;
      nasal continuous positive airway pressure (NCPAP). The current standard method of surfactant&#xD;
      delivery requires tracheal intubation and at least brief positive-pressure ventilation.&#xD;
      Tracheal intubation causes pain and leads to vagal-mediated physiologic instability in&#xD;
      neonates; therefore, premedication with morphine and atropine is routinely practiced in our&#xD;
      setting. However, premedication with morphine often increases respiratory depression,&#xD;
      requiring sustained mechanical ventilation. The Laryngeal Mask Airway (LMA) is a commercially&#xD;
      available, less invasive artificial airway that does not need to be inserted into the&#xD;
      trachea; it is FDA-approved for use in neonates, and preliminary data suggest that it can be&#xD;
      used for surfactant administration.&#xD;
&#xD;
      The main objective of this study protocol is reduce the need for endotracheal intubation and&#xD;
      mechanical ventilation in preterm neonates with mild to moderate RDS needing rescue&#xD;
      surfactant therapy by instilling surfactant though an LMA. A second objective is to compare&#xD;
      the efficacy of surfactant administered via LMA versus endotracheal tube (ETT) in decreasing&#xD;
      the severity of RDS. Additionally, we will evaluate the safety of surfactant administration&#xD;
      via LMA.&#xD;
&#xD;
      The primary hypothesis is that surfactant treatment via the LMA approach will decrease the&#xD;
      proportion of babies with RDS who require mechanical ventilation or subsequent intubation,&#xD;
      when compared with standard surfactant as administered to the ETT group.&#xD;
&#xD;
      This randomized controlled trial will include babies with mild-to-moderate RDS, between 4 to&#xD;
      48 hours of age, with gestational age 29 0/7 to 36 6/7 weeks, treated with NCPAP ≥ 5 cm H2O&#xD;
      and FiO2 between 0.30 and 0.60 for at least 2 hours to maintain SpO2 88-95%, and informed&#xD;
      consent. Exclusion criteria are weight &lt; 1000 g, airway anomalies, pulmonary air leaks, and&#xD;
      craniofacial and cardiothoracic malformations.&#xD;
&#xD;
      After informed consent is obtained, babies are randomly assigned (from sealed, opaque,&#xD;
      consecutively numbered envelopes), to the &quot;ETT&quot; or &quot;LMA&quot;. The &quot;ETT&quot; group is managed&#xD;
      according to our current practice of surfactant therapy (endotracheal intubation following&#xD;
      premedication with atropine + morphine), whereas the &quot;LMA&quot; group will be pre-medicated with&#xD;
      atropine before LMA insertion for surfactant administration.&#xD;
&#xD;
      Both groups will receive Infasurf (3mL/kg) instilled in 2 aliquots via their respective&#xD;
      airway, followed by PPV for at least 5 minutes. The artificial airway will be removed and the&#xD;
      patient returned to NCPAP by 15 minutes, if spontaneous respirations are adequate.&#xD;
      Indications for surfactant re-dosing and mechanical ventilation will be equivalent for both&#xD;
      groups.&#xD;
&#xD;
      Babies will continue or initiate assisted ventilation via ETT if any of the following occurs:&#xD;
&#xD;
        -  Persistent apnea;&#xD;
&#xD;
        -  Severe retractions;&#xD;
&#xD;
        -  Inability to wean FiO2 &lt; 60%&#xD;
&#xD;
      Criteria for re-dosing with surfactant:&#xD;
&#xD;
        1. Within 8 hours after first dose of surfactant (early re-dosing):&#xD;
&#xD;
             -  FiO2 20% higher than the baseline FiO2, after excluding other obvious causes of&#xD;
                respiratory insufficiency such as pneumothorax.&#xD;
&#xD;
           If early re-dosing of surfactant is needed in patients of either group, the dose will be&#xD;
           administered via ETT (i.e., LMA patients will be intubated, and will receive the dose of&#xD;
           surfactant via ETT)&#xD;
&#xD;
        2. Beyond 8 hours of the first dose of surfactant (late re-dosing):&#xD;
&#xD;
             -  FiO2 is ≥ 60%, or;&#xD;
&#xD;
             -  FiO2is ≥ 30% associated with worsening clinical signs of RDS.&#xD;
&#xD;
      If late re-dosing is needed in patients of the LMA group, use of the LMA is permitted for the&#xD;
      second dose. In the ETT group, all doses are given via the ETT.&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate of failure of early surfactant rescue therapy in the 2 groups, using the following&#xD;
      criteria to differentiate early from late failure:&#xD;
&#xD;
        -  Criteria for early failure (within 1 hour):&#xD;
&#xD;
             1. The need of mechanical ventilation within 1 hour of surfactant therapy.&#xD;
&#xD;
             2. Use of Narcan to avoid mechanical ventilation after surfactant therapy.&#xD;
&#xD;
        -  Criteria for late failure (beyond 1 hour):&#xD;
&#xD;
             1. Sustained FiO2 &gt; 0.60 to maintain target SpO2&#xD;
&#xD;
             2. Second dose of surfactant within 8 hours after the first dose.&#xD;
&#xD;
             3. More than 2 doses of surfactant.&#xD;
&#xD;
      Babies will have FiO2 adjusted to maintain SpO2 88-95%, per current practice. Other aspects&#xD;
      of weaning ventilatory support will be managed by clinicians' preference.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 &gt; 0.60 to Maintain Target SpO2, or Second Dose of Surfactant Within 8 Hours, or Needing More Than 2 Doses of Surfactant).</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Surfactant Doses</measure>
    <time_frame>96 hr</time_frame>
    <description>Mean number of surfactant doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Assisted Ventilation</measure>
    <time_frame>2 months</time_frame>
    <description>Days on any respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Supplemental Oxygen</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pneumothorax</measure>
    <time_frame>96 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of BPD (O2 Dependence at the Later of 28 Days of Age or 36 Weeks Postmenstrual Age)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications During Insertion of LMA</measure>
    <time_frame>96 hrs</time_frame>
    <description>LMA insertion complications (e.g. trauma, failure of insertion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>Endotracheal intubation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laryngeal mask airway</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tube insertion</intervention_name>
    <description>Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
    <arm_group_label>Endotracheal intubation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laryngeal mask airway insertion</intervention_name>
    <description>Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
    <arm_group_label>Laryngeal mask airway</arm_group_label>
    <other_name>LMA North America</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild-to-moderate RDS&#xD;
&#xD;
          -  Postnatal age 4 to 48 hours&#xD;
&#xD;
          -  Gestational age 29 0/7 to 36 6/7 weeks&#xD;
&#xD;
          -  Treated with nasal CPAP ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 hours&#xD;
             to maintain SpO2 88-95%&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weight &lt; 1000 g&#xD;
&#xD;
          -  Airway anomalies&#xD;
&#xD;
          -  Pulmonary air leaks&#xD;
&#xD;
          -  Craniofacial or cardiothoracic malformations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquim M Pinheiro, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Querube Santana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <results_first_submitted>June 16, 2014</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2014</results_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albany Medical College</investigator_affiliation>
    <investigator_full_name>Joaquim M.B. Pinheiro</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Respiratory distress syndrome</keyword>
  <keyword>Surfactant</keyword>
  <keyword>Tracheal intubation</keyword>
  <keyword>Laryngeal mask airway</keyword>
  <keyword>Newborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant excluded and removed from study after randomization due to ineligibility (pre-existing pneumothorax)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Endotracheal Intubation</title>
          <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
        </group>
        <group group_id="P2">
          <title>Laryngeal Mask Airway</title>
          <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Single ineligible patient excluded in the endotracheal intubation group</population>
      <group_list>
        <group group_id="B1">
          <title>Endotracheal Intubation</title>
          <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
        </group>
        <group group_id="B2">
          <title>Laryngeal Mask Airway</title>
          <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gestational age &lt;33 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gestational age &gt;=33 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 &gt; 0.60 to Maintain Target SpO2, or Second Dose of Surfactant Within 8 Hours, or Needing More Than 2 Doses of Surfactant).</title>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 &gt; 0.60 to Maintain Target SpO2, or Second Dose of Surfactant Within 8 Hours, or Needing More Than 2 Doses of Surfactant).</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Surfactant Doses</title>
        <description>Mean number of surfactant doses</description>
        <time_frame>96 hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Surfactant Doses</title>
          <description>Mean number of surfactant doses</description>
          <units>mean doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread=".6"/>
                    <measurement group_id="O2" value="1.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Assisted Ventilation</title>
        <description>Days on any respiratory support</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Days on Assisted Ventilation</title>
          <description>Days on any respiratory support</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7" upper_limit="21"/>
                    <measurement group_id="O2" value="8.5" lower_limit="6" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Supplemental Oxygen</title>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Days on Supplemental Oxygen</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6" upper_limit="20"/>
                    <measurement group_id="O2" value="7.5" lower_limit="4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Pneumothorax</title>
        <time_frame>96 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Pneumothorax</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of BPD (O2 Dependence at the Later of 28 Days of Age or 36 Weeks Postmenstrual Age)</title>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of BPD (O2 Dependence at the Later of 28 Days of Age or 36 Weeks Postmenstrual Age)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications During Insertion of LMA</title>
        <description>LMA insertion complications (e.g. trauma, failure of insertion)</description>
        <time_frame>96 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Complications During Insertion of LMA</title>
          <description>LMA insertion complications (e.g. trauma, failure of insertion)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Rate</title>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endotracheal Intubation</title>
            <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Laryngeal Mask Airway</title>
            <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Endotracheal Intubation</title>
          <description>Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication&#xD;
Endotracheal tube insertion: Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)</description>
        </group>
        <group group_id="E2">
          <title>Laryngeal Mask Airway</title>
          <description>Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication&#xD;
Laryngeal mask airway insertion: Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <description>Pneumothorax after randomization</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joaquim Pinheiro, MD, MPH</name_or_title>
      <organization>Albany Medical Center</organization>
      <phone>518-262-5421</phone>
      <email>pinheij@mail.amc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

